DiaGyn is developing a wide range of solutions to unmet needs demanded by clinical practice in the field of Women’s Health.

Worldwide, every sixth death is due to cancer, making it the second leading cause of death; with almost 9 million deaths per year.

Due to population growth and aging it is estimated that global burden of cancer will increase with new death cases of around 14 million by 2030.

Cancer survival rates may change according to the cancer type and the stage of the disease at diagnosis.

Recurrence of the disease occurs in more than 70% of the patients achieving response to treatment.

DiaGyn is focusing on integrating drug development and molecular genomics with personalized therapeutic approaches, addressing BRCA1/2 Mutations, Ovarian and Breast Cancer.